Morris J C, Storandt M, Miller J P, McKeel D W, Price J L, Rubin E H, Berg L
Alzheimer's Disease Research Center, Washington University School of Medicine, 4488 Forest Park Ave, Suite 130, St Louis, MO 63178, USA.
Arch Neurol. 2001 Mar;58(3):397-405. doi: 10.1001/archneur.58.3.397.
Mild cognitive impairment (MCI) is considered to be a transitional stage between aging and Alzheimer disease (AD).
To determine whether MCI represents early-stage AD by examining its natural history and neuropathologic basis.
A prospective clinical and psychometric study of community-living elderly volunteers, both nondemented and minimally cognitively impaired, followed up for up to 9.5 years. Neuropathologic examinations were performed on participants who had undergone autopsy.
An AD research center.
All participants enrolled between July 1990 and June 1997 with Clinical Dementia Rating (CDR) scores of 0 (cognitively healthy; n = 177; mean age, 78.9 years) or 0.5 (equivalent to MCI; n = 277; mean age, 76.9 years). Based on the degree of clinical confidence that MCI represented dementia of the Alzheimer type (DAT), 3 subgroups of individuals with CDR scores of 0.5 were identified: CDR 0.5/DAT, CDR 0.5/incipient DAT, and CDR 0.5/uncertain dementia.
Progression to the stage of CDR 1, which characterizes mild definite DAT.
Survival analysis showed that 100% of CDR 0.5/DAT participants progressed to greater dementia severity over a 9.5-year period. At 5 years, rates of progression to a score of CDR 1 (or greater) for DAT were 60.5% (95% confidence interval [CI], 50.2%-70.8%) for the CDR 0.5/DAT group, 35.7% (95% CI, 21.0%-50.3%) for the CDR 0.5/incipient DAT group, 19.9% (95% CI, 8.0%-31.8%) for the CDR 0.5/uncertain dementia group, and 6.8% (95% CI, 2.2%-11.3%) for CDR 0/controls. Progression to greater dementia severity correlated with degree of cognitive impairment at baseline. Twenty-four of the 25 participants with scores of CDR 0.5 had a neuropathologic dementing disorder, which was AD in 21 (84%).
Individuals currently characterized as having MCI progress steadily to greater stages of dementia severity at rates dependent on the level of cognitive impairment at entry and they almost always have the neuropathologic features of AD. We conclude that MCI generally represents early-stage AD.
轻度认知障碍(MCI)被认为是衰老与阿尔茨海默病(AD)之间的过渡阶段。
通过研究MCI的自然病程和神经病理学基础,确定其是否代表AD的早期阶段。
对社区居住的老年志愿者进行前瞻性临床和心理测量研究,这些志愿者均无痴呆或仅有轻微认知障碍,随访时间长达9.5年。对已进行尸检的参与者进行神经病理学检查。
一个AD研究中心。
所有在1990年7月至1997年6月期间入组的参与者,临床痴呆评定量表(CDR)评分为0(认知健康;n = 177;平均年龄78.9岁)或0.5(相当于MCI;n = 277;平均年龄76.9岁)。根据临床对MCI代表阿尔茨海默型痴呆(DAT)的置信程度,将CDR评分为0.5的个体分为3个亚组:CDR 0.5/DAT、CDR 0.5/早期DAT和CDR 0.5/痴呆不确定。
进展至CDR 1阶段,这是轻度明确DAT的特征。
生存分析显示,100%的CDR 0.5/DAT参与者在9.5年期间病情进展至更严重的痴呆程度。5年时,CDR 0.5/DAT组进展至CDR 1(或更高)评分的DAT发生率为60.5%(95%置信区间[CI],50.2%-70.8%),CDR 0.5/早期DAT组为35.7%(95% CI,21.0%-50.3%),CDR 0.5/痴呆不确定组为19.9%(95% CI,8.0%-31.8%),CDR 0/对照组为6.8%(95% CI,2.2%-11.3%)。进展至更严重的痴呆程度与基线时的认知障碍程度相关。25名CDR评分为0.5的参与者中有24人患有神经病理学痴呆症,其中21人(84%)为AD。
目前被归类为MCI的个体以与入组时认知障碍程度相关的速率稳步进展至更严重的痴呆阶段,并且他们几乎总是具有AD的神经病理学特征。我们得出结论,MCI通常代表AD的早期阶段。